研究单位：[1]Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology Wuhan,Hubei,China,430030[2]Beijing 302 Military Hospital of China Beijing,Beijing,China[3]Beijing BeiJing YouAn Hospital,Capital Medical University Beijing,Beijing,China[4]Chongqing The First Hospital Affiliated to AMU Chongqing,Chongqing,China[5]Fujian The First Affiliated Hospital of Fujian Medical University Fuzhou,Fujian,China[6]Guangxi The First Affiliated Hospital of Guangxi Medical University Nanning,Guangxi,China[7]HangzhouThe First Affiliated Hospital of College of Medicine,Zhejiang University Zhejiang,Hangzhou,China[8]Hunan Departmen of infectious disease,Xiangya Hospital,Central-south Universit Changsha,Hunan,China[9]Hunan The Second Xiangya Hospital of Central South University Changsha,Hunan,China[10]JiangsuThe First Affiliated Hospital with Nanjing Medical University Nanjing,Jiangsu,China[11]Jiangsu The Second Hospital of Nanjing Nanjing,Jiangsu,China[12]Xiamen Traditional Chinese Medicine,Xiamen Hospital Shantou,Xiamen,China[13]Zhejiang The first affiliated hospital of Wenzhou medical universtiy Wenzhou,Zhejiang,China
研究目的：
The aim of the prospective real-world study is to evaluate whether sequential combination therapy with pegylated interferon plus entecavir/tenofovir could induce higher rates of HBsAg loss in nucleoside-treated patients with chronic hepatitis B compared to continuous nucleoside treatment
